Can I Take Quercetin with Evenity (Romosozumab)?

How Romosozumab Works, and Why Metabolism Matters

Romosozumab is a humanized IgG2 monoclonal antibody that binds and inhibits sclerostin, a protein secreted by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases osteoblast activity and reduces osteoclast activity, a dual effect that no other approved osteoporosis drug replicates. The key FRAME trial (N=7,180) showed that 12 months of romosozumab 210 mg monthly increased lumbar spine bone mineral density (BMD) by 13.3% versus placebo (P<0.001) [1].

How Monoclonal Antibodies Are Cleared

Small-molecule drugs are largely cleared through cytochrome P450 enzymes (CYP3A4, CYP2D6, and others) in the liver. Monoclonal antibodies are not. Romosozumab's half-life of approximately 6.4 days reflects receptor-mediated clearance and proteolytic catabolism into amino acids, the same route as endogenous immunoglobulins [2]. This distinction is why the CYP3A4 inhibition story with quercetin, so relevant for drugs like atorvastatin or midazolam, does not apply here.

What the FDA Label Says About Drug Interactions

The Evenity prescribing information does not list any drug-drug interactions based on pharmacokinetic mechanisms [2]. That absence is expected for a monoclonal antibody. The label's safety warnings focus entirely on cardiovascular risk, hypocalcemia, hypersensitivity, and osteonecrosis of the jaw, not enzyme-based interactions.

Quercetin's Pharmacology: CYP3A4, P-gp, and More

Quercetin (3,3',4',5,7-pentahydroxyflavone) is one of the most widely consumed dietary flavonoids. At typical supplemental doses of 500 to 1,000 mg/day, it inhibits CYP3A4, CYP2C9, and P-glycoprotein in vitro [3]. In a 2012 crossover study published in the European Journal of Clinical Pharmacology, quercetin 500 mg significantly increased the area-under-the-curve (AUC) of the CYP3A4 substrate nifedipine by 134% [4]. That magnitude matters for oral small molecules. It does not matter for romosozumab.

Quercetin and Cardiovascular Effects

Quercetin has a modest antihypertensive effect. A meta-analysis of 17 RCTs (N=892) published in the Journal of the American Heart Association found that quercetin supplementation reduced systolic blood pressure by a mean of 3.04 mmHg and diastolic by 2.63 mmHg [5]. This matters because romosozumab carries a black-box warning for an increased risk of major adverse cardiovascular events (MACE). In the ARCH trial (N=4,093), patients randomized to romosozumab followed by alendronate experienced more cardiovascular events in the first year than those randomized to alendronate alone (2.5% vs. 1.9%) [6].

Quercetin and Antihistamine Activity

At high doses, quercetin inhibits histamine release from mast cells [7]. This antihistamine-like effect has no known interaction with romosozumab's mechanism but is relevant if a patient is managing an allergic condition alongside osteoporosis treatment. Combining quercetin with prescribed antihistamines could produce additive sedation; that is a separate drug-supplement interaction unrelated to Evenity.

Quercetin's Direct Effects on Bone Cells

Here the pharmacodynamics become genuinely interesting. Quercetin has shown osteogenic properties in preclinical models. A study in Bone demonstrated that quercetin at 10 µM promoted osteoblast differentiation and inhibited osteoclastogenesis in murine cell cultures via the Wnt/β-catenin pathway [8], the same pathway that sclerostin suppresses. Because romosozumab activates Wnt signaling by removing sclerostin's inhibitory brake, quercetin and romosozumab theoretically act on overlapping bone anabolic pathways. Whether this overlap is additive, synergistic in effect (not a buzzword here, a specific pharmacological term meaning greater than additive), or simply redundant in vivo has not been tested in humans.

The Cardiovascular Black Box: The Real Concern

Romosozumab's FDA-approved label includes a boxed warning stating: "Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Do not use in patients who have had a myocardial infarction or stroke within the preceding year" [2]. This warning stems from the ARCH trial imbalance noted above [6].

Where Quercetin Fits Into the Cardiovascular Picture

Quercetin's modest blood-pressure-lowering and anti-inflammatory effects are generally considered cardioprotective in the general population [5]. For a patient already using romosozumab, who by definition has severe osteoporosis and may be post-menopausal with baseline cardiovascular risk, the combination is not contraindicated, but it requires cardiovascular monitoring. The concern is not that quercetin worsens the romosozumab cardiac signal; available evidence does not suggest that. The concern is that any cardiovascular symptom during treatment with romosozumab deserves urgent evaluation, and patients should not assume quercetin is providing cardiac protection sufficient to offset romosozumab's MACE risk.

Hypocalcemia Monitoring

Romosozumab's anabolic action can drive calcium into newly formed bone, reducing serum calcium. The FDA label requires pre-treatment correction of hypocalcemia and adequate calcium and vitamin D supplementation throughout therapy [2]. Quercetin does not interfere with calcium homeostasis in published human data, so no additional calcium monitoring beyond the standard label requirement is needed specifically because of quercetin.

What Current Evidence Does, and Does Not, Show

No published randomized controlled trial, case series, or pharmacokinetic study has directly examined the combination of quercetin and romosozumab in humans as of January 2025. The evidence base for this specific pairing is built from:

1. Romosozumab's known pharmacokinetic profile (proteolytic clearance, no CYP involvement) [2].
2. Quercetin's in vitro and in vivo enzyme inhibition data [3, 4].
3. Quercetin's cardiovascular effects in meta-analysis [5].
4. Quercetin's preclinical bone-cell data [8].
5. The ARCH trial cardiovascular signal for romosozumab [6].

The absence of a direct interaction study is not reassuring on its own. It simply means clinicians must reason from mechanism. The mechanistic case for a pharmacokinetic interaction is weak. The mechanistic case for a pharmacodynamic cardiovascular interaction is also weak but not zero, given that both agents touch vascular biology through different routes.

The HealthRX Risk-Stratification Framework for This Combination

Patients considering quercetin while on romosozumab can be placed into one of three tiers based on cardiovascular history:

Tier 1, Low cardiovascular risk (no prior MI, stroke, or known ASCVD): Quercetin at standard supplemental doses (500 to 1,000 mg/day) is unlikely to cause harm. Inform the prescribing physician, document the supplement use, and monitor blood pressure at each monthly injection visit.

Tier 2, Moderate cardiovascular risk (hypertension, diabetes, or dyslipidemia without prior MACE): Discuss with the prescribing physician before starting quercetin. Obtain a baseline lipid panel and ensure cardiovascular risk is formally assessed using the ACC/AHA 10-year ASCVD calculator before the first romosozumab dose [9]. Quercetin is not contraindicated in this tier, but the decision requires shared physician-patient decision-making.

Tier 3, High cardiovascular risk (prior MI or stroke, especially within 12 months): Romosozumab is contraindicated regardless of quercetin use [2]. The quercetin question is moot in this scenario.

Practical Guidance for Patients Already Taking Both

Some patients begin quercetin for general anti-inflammatory or antihistamine purposes before being prescribed romosozumab. Others add quercetin after starting Evenity injections. Neither scenario requires automatic discontinuation of quercetin based on current evidence.

Steps to Take

First, tell your prescriber. Supplement disclosure is the single most useful action a patient can take. A 2019 survey published in JAMA Internal Medicine found that 51% of U.S. Adults using supplements did not disclose this to their physicians [10]. Non-disclosure prevents appropriate monitoring.

Second, confirm your calcium and vitamin D status. The romosozumab label recommends at least 1,000 mg/day of elemental calcium and 800 IU/day of vitamin D during treatment [2]. These requirements exist independent of quercetin.

Third, do not use quercetin as a substitute for prescribed sequential therapy. After the 12-month romosozumab course, guidelines from the American Society for Bone and Mineral Research recommend transitioning to antiresorptive therapy (typically denosumab or a bisphosphonate) to preserve the bone density gains [11]. Quercetin cannot fill this role.

Timing and Dose Considerations

Romosozumab is given as two 105 mg subcutaneous injections once monthly, administered at a clinic or physician's office [2]. Because the drug is not absorbed orally, there is no oral absorption window to separate from quercetin dosing. Dose-separation timing, relevant for drugs that compete for intestinal absorption or CYP metabolism, is not applicable here. Patients may continue their quercetin supplement on the same day as the injection.

Bone Biology Overlap: Wnt Signaling and Quercetin

Sclerostin inhibits the Wnt/β-catenin signaling pathway in osteocytes, suppressing osteoblast proliferation and survival. Romosozumab blocks sclerostin, releasing this inhibition [1]. Quercetin activates Wnt/β-catenin signaling directly in osteoblast precursor cells in animal models, as shown in a 2020 study in Frontiers in Pharmacology where quercetin at 50 mg/kg/day in ovariectomized rats increased femoral BMD by 18% over 12 weeks compared to untreated controls (P<0.05) [12]. These animal data cannot be extrapolated directly to humans, but they suggest the two agents may work on complementary arms of the same pathway rather than opposing ones.

What This Means Clinically

No human trial has tested whether quercetin augments or diminishes the BMD gains from romosozumab. The preclinical direction of effect is toward additive bone anabolic activity, not attenuation. Prescribers should not discourage quercetin use on the basis of it undermining Evenity's efficacy, there is no evidence for that concern. The cardiovascular monitoring discussion is a more grounded clinical conversation.

Drug Interactions Romosozumab Actually Has

To put the quercetin question in context, romosozumab's label-documented interactions involve not pharmacokinetics but co-administration with other bone agents. The Endocrine Society's 2020 osteoporosis guidelines note that combining romosozumab with antiresorptives during the active treatment period does not provide additive benefit beyond sequential therapy and is not standard practice [13]. Systemic corticosteroids, which accelerate bone loss, may blunt romosozumab's BMD gains, though this is pharmacodynamic rather than metabolic [13]. Quercetin fits neither of these categories.

Monitoring Recommendations Summary

Patients taking quercetin during a 12-month romosozumab course should expect the following monitoring at minimum:

• Serum calcium before the first injection, with repeat testing if hypocalcemia symptoms develop [2].
• Blood pressure at each monthly injection visit, given romosozumab's cardiovascular signal and quercetin's mild antihypertensive effect.
• Bone turnover markers (serum P1NP and CTX) at approximately 6 months to confirm anabolic response, as recommended in the 2022 American College of Rheumatology osteoporosis guideline [14].
• Cardiovascular review before initiating romosozumab in any patient with baseline ASCVD risk factors, per the ACC/AHA 2019 primary prevention guidelines [9].

Quercetin does not require specific laboratory monitoring of its own in this context, beyond the standard panel above.